Illumina delivers 2021 results - GuruFocus.com
GuruFocus Article or News written by PRNewswire and the topic is about:
Source: gurufocus.com
Page 4 - Accelerate Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Accelerate Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Accelerate Access Today - Breaking & Trending Today
Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference
/PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the company's strong growth trajectory, including 2021...
Source: prnewswire.com
Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
Molnupiravir was the first oral COVID-19 antiviral medicine to receive authorization on Nov. 4, when the U.K.’s Medicines and Healthcare Products Regulatory Agency granted authorization.
Source: republicworld.com
Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
24.12.2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Japan’s Ministry of Health, Labor and Welfare has granted Special Approval for Emergency in Japan for molnupiravir, an ...
Source: wallstreet-online.de